![Joshua Moriarty](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Joshua H.
Moriarty is currently the Chief Operating Officer & Director at Okogen, Inc.
Actieve functies van Joshua Moriarty
Bedrijven | Functie | Begin |
---|---|---|
Okogen, Inc.
![]() Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Operationeel Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Okogen, Inc.
![]() Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Commercial Services |